(Q39844074)

English

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

scientific article published on August 25, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study (English)

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

phase I clinical trial

0 references

phase II clinical trial

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

1

object named as

Sagar Lonial

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Edmund K Waller

14

object named as

Edmund K. Waller

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

author name string

Jonathan Kaufman

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Mourad Tighiouart

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Ajay Nooka

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Claire Torre

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Stephanie McMillan

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Heather Renfroe

9

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Amelia A. Langston

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

Leonard T. Heffner

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

R. Donald Harvey

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

Mary J. Lechowicz

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

H. Jean Khoury

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

Christopher R. Flowers

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

language of work or name

0 references

publication date

25 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

full work available at URL

http://clincancerres.aacrjournals.org/content/clincanres/16/20/5079.full.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/20/5079

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20739431

23 June 2024

https://aacrjournals.org/clincancerres/article-pdf/16/20/5079/3396060/5079.pdf

Portable Document Format

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

5079-5086

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma

2

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

3

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

4

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

5

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.

6

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Evolving role of stem cell transplantation in multiple myeloma

7

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea phase II trial.

8

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

9

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

10

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

11

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

12

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes

13

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

14

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

15

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

16

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

17

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

A phase 2 study of bortezomib in relapsed, refractory myeloma

18

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

19

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

22

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

23

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma

25

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Cancer phase I clinical trials: efficient dose escalation with overdose control.

26

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Patient specific dosing in a cancer phase I clinical trial

27

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

28

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Impact of additional cytoreduction following autologous SCT in multiple myeloma.

30

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

31

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells

34

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.

35

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

36

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

37

1 reference

10.1158/1078-0432.CCR-10-1662

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-1662

23 June 2024

Identifiers

10.1158/1078-0432.CCR-10-1662

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39844074&oldid=2191642699"